Literature DB >> 3007826

Epstein-Barr virus-related antibody pattern in uveitis.

M Sunakawa, S Okinami.   

Abstract

Epstein-Barr virus-related antibody titers were determined in 30 patients with anterior uveitis, 45 with pan-uveitis, including 19 with Behçet's disease, 11 with Vogt-Koyanagi-Harada's disease and 15 with unclassified pan-uveitis, and 144 age-matched healthy controls. The frequencies of anti-VCA (viro-capsid antigen) and anti-EA (early antigen) in uveitis patients and in controls were similar, but the frequency of sera with elevated titers (greater than or equal to 1:160) and the geometric mean titer of anti-VCA in the patients with anterior uveitis was significantly higher than in the controls (P less than 0.025, P less than 0.01) and in the patients with pan-uveitis (P less than 0.001). The frequency of sera with elevated titers of anti-EBNA (Epstein-Barr virus associated nuclear antigen) (greater than or equal to 1:160) in the patients with pan-uveitis was significantly lower than in the controls (P less than 0.02) and in the patients with anterior uveitis (P less than 0.01). Among the patients with pan-uveitis, there was no significant difference in the pattern of antibodies. These data are compatible with the interpretation that there may be both anatomical and immunological differences between anterior and pan-uveitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3007826

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  2 in total

1.  Increased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis.

Authors:  J V Ongkosuwito; A Van der Lelij; M Bruinenberg; M Wienesen-van Doorn; E J Feron; C B Hoyng; R J de Keizer; A M Klok; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

2.  HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia.

Authors:  Alia Iqniebi; Ameera Gaafar; Atia Sheereen; Abdullah Al-Suliman; Gamal Mohamed; Khaled Al-Hussein; Khalid F Tabbara
Journal:  Mol Vis       Date:  2009-09-12       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.